Table 1.
Patient characteristics at transplant n (%)
| Median age (range) | 56 (18-72) |
| Sex, M/F | 198/129 |
| Diagnosis | |
| Multiple myeloma | 201 (61) |
| B-cell non-Hodgkin's lymphoma | 80 (25) |
| Hodgkin's lymphoma | 27 (8) |
| T-cell non-Hodgkin's lymphoma | 19 (6) |
| CMV IgG seropositivity1 | 304 (93) |
| HBcIgG serositivity | 46 (14) |
| HCVAb seropositivity1 | 5 (1.5) |
| Disease status | |
| Complete response | 205 (63) |
| Partial response | 114 (35) |
| Stable/progressive disease | 8 (2) |
| Prior chemotherapy lines | |
| 1 | 185 (57) |
| 2 | 120 (37) |
| ≥ 3 | 22 (6) |
| Prior fludarabine treatment | 5 (1.5) |
| Prior alemtuzumab treatment | 0 |
| Conditioning regimen | |
| BEAM or BEAM-like | 126 (39) |
| MEL200/MEL100 | 201 (61) |
| Median CD34+ infused cells × 106/kg (range) | 5.62 (2.36-28.48) |
1
Datum is missing in 2 patients. BEAM: Carmustine, Etoposide, Cytarabine, Melphalan; MEL200: Melphalan 200 mg/m2; MEL100: Melphalan 100 mg/m2; CMV: Cytomegalovirus.